Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01389700
Recruitment Status : Terminated (Difficulty in patient recruitment in the participating sites)
First Posted : July 8, 2011
Last Update Posted : December 12, 2014
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

- To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation

Secondary Objectives:

  • To determine the safety and tolerability of SAR279356
  • To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356
  • Exploratory efficacy of SAR279356 on prevention of bacterial infections

Condition or disease Intervention/treatment Phase
Infection Prophylaxis Drug: SAR279356 Drug: placebo Phase 2

Detailed Description:

Total study duration (from screening to last follow-up visit) is 91 days break down as follows:

  • Screening: 1 day prior to dosing;
  • Treatment period: one IV injection on Day 1;
  • Follow-up period: 90 days

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation
Study Start Date : October 2011
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Experimental: SAR279356 dose 1
SAR279356 dose 1, single administration
Drug: SAR279356

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Experimental: SAR279356 dose 2
SAR279356 dose 2, single administration
Drug: SAR279356

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Placebo Comparator: Placebo
Matching placebo, single administration
Drug: placebo

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Primary Outcome Measures :
  1. Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. Opsonophagocytic assay (OPA) [ Time Frame: 90 days ]
  2. Opsonophagocytic killing assay (OPK) [ Time Frame: 90 days ]
  3. Dosage of human anti-human antibodies (HAHA) [ Time Frame: 90 days ]
  4. Occurrence of infections [ Time Frame: Up to 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria :

  • ICU patients on mechanical ventilation at the time of randomization
  • Patients or legally authorized representative (LAR) giving written informed consent.

Exclusion criteria:

  • Patients <18 years of age;
  • Documented Pseudomonas infection or colonization in the last 30 days;
  • Immunocompromised patients
  • Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies;
  • Patient who has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 half-lives, whichever is longer;
  • Patient or LAR who withdraws consent during the screening (starting from signed informed consent form);
  • Acute liver injury related criteria at the time of study entry:
  • Pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01389700

Layout table for location information
United States, California
Investigational Site Number 840010
Los Angeles, California, United States, 90024
Investigational Site Number 840020
Stanford, California, United States, 94305
United States, Florida
Investigational Site Number 840006
Jacksonville, Florida, United States, 32209
United States, Kentucky
Investigational Site Number 840001
Pikeville, Kentucky, United States, 41501
United States, Montana
Investigational Site Number 840009
Butte, Montana, United States, 59701
United States, New Jersey
Investigational Site Number 840003
Camden, New Jersey, United States, 08103
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT01389700    
Other Study ID Numbers: PKD11791
U1111-1118-6717 ( Other Identifier: UTN )
First Posted: July 8, 2011    Key Record Dates
Last Update Posted: December 12, 2014
Last Verified: November 2014